Stockscreener 앱 받기
294.64
1.65%
-4.93
시간 외 거래:
294.64
Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스
Madrigal Pharmaceuticals, Inc. (MDGL): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside Potential - Yahoo Finance
Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential - Insider Monkey
Madrigal Pharmaceuticals (MDGL): Among Billionaire John Paulson’s Stocks with Huge Upside Potential - Insider Monkey
Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra (NASDAQ:MDGL) - Seeking Alpha
Billionaire John Paulson’s 10 Stocks with Huge Upside Potential - Insider Monkey
Earnings Beat: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2025 Earnings Call Transcript - Insider Monkey
Decoding Madrigal Pharmaceuticals Inc (MDGL): A Strategic SWOT I - GuruFocus
(MDGL) Trading Signals - news.stocktradersdaily.com
Madrigal Pharmaceuticals (MDGL): UBS Maintains Buy Rating, Raise - GuruFocus
Madrigal Pharmaceuticals (MDGL): UBS Maintains Buy Rating, Raises Price Target | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals (MDGL) Target Price Raised by Canaccord - GuruFocus
Madrigal Pharmaceuticals (MDGL) Receives a Price Target Boost fr - GuruFocus
Madrigal Pharmaceuticals (MDGL) Receives a Price Target Boost from B. Riley Securities | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals (MDGL) Sees Price Target Boost on Stron - GuruFocus
UBS Increases Price Target for Madrigal Pharmaceuticals (MDGL) | - GuruFocus
UBS Increases Price Target for Madrigal Pharmaceuticals (MDGL) | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals (MDGL) Sees Price Target Boost on Strong Sales | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals to Present Breakthrough Resmetirom Data at EASL Congress 2025 - MSN
UBS Adjusts Madrigal Pharmaceuticals Price Target to $458 From $441, Maintains Buy Rating - marketscreener.com
Madrigal Pharmaceuticals (MDGL) Receives Increased Price Target from Analyst | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals Inc (MDGL) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
Madrigal Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Madrigal: Q1 Earnings Snapshot - Huron Daily Tribune
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up - Zacks Investment Research
Madrigal Pharmaceuticals Q1 Loss Narrows - marketscreener.com
Earnings call transcript: Madrigal Pharmaceuticals beats Q1 2025 EPS forecasts - Investing.com
Madrigal Pharmaceuticals Inc Q1 2025 Earnings: Revenue Surpasses - GuruFocus
Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates - The Manila Times
Madrigal Pharmaceuticals (MDGL) Reports Strong Q1 Revenue Exceed - GuruFocus
Madrigal’s MASH drug sales again top Wall Street projections - Yahoo Finance
Madrigal stock holds neutral as 1Q revenue beats estimates By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals (MDGL) to Present Key Findings at EASL - GuruFocus
Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress - The Manila Times
Madrigal to Present Late-Breaking Resmetirom Data in - GlobeNewswire
Insiders At Madrigal Pharmaceuticals Sold US$4.4m In Stock, Alluding To Potential Weakness - simplywall.st
Citizens JMP reiterates Madrigal stock with $443 target By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals to Announce Q1 2025 Results with Live Webcast - MSN
Leadership Changes at Madrigal Pharmaceuticals Mark New Phase of Growth - MSN
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals to Release Q1 2025 Financial Results on May 1, 2025 - Nasdaq
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 - GlobeNewswire
Madrigal Pharmaceuticals announces executive transition By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals announces executive transition - Investing.com Australia
Madrigal Pharmaceuticals Announces Leadership Transition - TipRanks
(MDGL) Technical Data - news.stocktradersdaily.com
Madrigal founder Rebecca Taub to step back; firm hires successor from Novartis - The Business Journals
Madrigal Pharmaceuticals Appoint Rebecca Taub, M.D. as Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed CMO - citybiz
Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer - The Manila Times
Madrigal Pharmaceuticals Announces Company Founder Rebecca - GlobeNewswire
0.84%
0.15%
자본화:
|
볼륨(24시간):